Successful treatment with tacrolimus of refractory adult-onset Still's disease

DOI QR Code

Ohe, Masashi (Department of General Medicine, Hokkaido Social Insurance Hospital) ;
Oku, Kenji (Department of Medicine II, Hokkaido University Graduate School of Medicine) ;
Kono, Michihito (Department of Medicine II, Hokkaido University Graduate School of Medicine) ;
Bohgaki, Toshiyuki (Department of Medicine II, Hokkaido University Graduate School of Medicine)

Murakami K, Fujii T, Yukawa N, et al. Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Mod Rheumatol 2007;17:167-170. https://doi.org/10.3109/s10165-006-0559-2
Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-430.
Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T. Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset Still's disease. Intern Med 2011;50:1757-1760. https://doi.org/10.2169/internalmedicine.50.4771
Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 2001;44:1716-1717. https://doi.org/10.1002/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I
Kuinose M, Iwagaki H, Morimoto Y, et al. Calcineurin antagonists inhibit interferon-gamma production by downregulation of interleukin-18 in human mixed lymphocyte reactions. Acta Med Okayama 2000;54:201-209.

Biologics for the treatment of adult-onset still’s disease vol.19, pp.11, 2014, https://doi.org/10.1080/14712598.2019.1652591